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Abstract
Background: To investigate the expression of MMP-14 and CD44 as well as epithelial-to-mesenchymal
transition(EMT)-like changes in ovarian cancer and to determine correlations with clinical outcome.
Methods: In 97 patients with ovarian cancer, MMP-14 and CD44 expression as determined by immunohistochemistry
was investigated in relation to EMT-like changes. To determine this, immunohistochemical staining of E-cadherin and
vimentin was performed.
Results: Patients with expression of both MMP-14 and CD44 in their tumors had a poor prognosis despite complete
debulking. Serous histology in advanced-stage tumors (FIGO IIB-IV) correlated with CD44 (rho .286, p < 0.01). Also, CD44
correlated with percentage vimentin expression (rho .217, p < 0.05).
In logistic regression analysis with complete debulking as the outcome parameter, CD44 expression was found to be
significant (OR 3,571 (95 % Confidence Interval 1,112–11,468) p = 0.032), though this was not the case for MMP-14 and
EMT parameters.
Conclusion: The subgroup of patients with double expression of MMP-14 and CD44 had a poor prognosis despite
complete debulking. Serous subtype in advanced-stage patients and CD44 expression were found to be correlated
with vimentin expression, and CD44 expression was found to be significantly correlated with complete debulking.
However, a significant correlation between EMT and clinical parameters was not found.
Keywords: MMP-14, CD44, Epithelial-to-mesenchymal transition, Ovarian cancer
Abbreviations: CD, Cluster of Differentiation; EMT, Epithelial-to-Mesenchymal-Transition; FIGO, International Federation
of Gynaecology and Obstetrics; MET, Mesenchymal-to-Epithelial-Transition; MMP, Matrix MetalloProteinase; OR, Odds
Ratio; OS, Overall Score; ROGY, Registration System Oncological Gynaecology; RT, Room temperature; SPSS, Statistical
Package for the Social Sciences
Background
In epithelial cancer, epithelial-to-mesenchymal transition
(EMT) is an important pathophysiological process. EMT
enables epithelial carcinoma cells to invade the underlying
stroma. Usually, EMT occurs at the tumor’s invasive front
and EMT can be recognized by its surrounding stromal
reaction in conventional histopathology. Often, EMT is
not complete and reversible and it is probably more
correct to describe the process in the tumor as EMT-like
changes [1].
In most other gynecological tumors, EMT-like changes
are found [1]. In ovarian cancer however, the invasive
front is less clearly defined than in other tumors of the
female genital tract. Also, the relationship between EMT
and prognosis has not been clearly established in ovarian
cancer [1].
During EMT-like changes, the structure of the tumor
cells is remodeled. Epithelial cells undergo a transformation
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from apical-basal to front-back polarity, and the actin cyto-
skeleton is restructured with a morphological change from
a rounded epithelial feature to a spindle shape with mesen-
chymal characteristics. At the cell’s front and leading edges,
lamellipodia are located, which are actin cytoskeleton pro-
trusions of the cell responsible for its movement [2].
EMT-like changes result in down-regulation of epithe-
lial markers such as E-cadherin and cytokeratins and
increased expression of mesenchymal markers such as
vimentin [1, 3, 4]. This is sometimes accompanied by an
up-regulation of matrix metalloproteinases (MMPs) [1]
and another important molecule in EMT, CD44 [5].
CD44 is a cell-surface molecule involved in intercellu-
lar interactions, cell adhesion and migration. In addition
to the standard form of CD44, splice variants are de-
scribed in the literature [6]. CD44 in its standard form
located on the surface of ovarian cancer cells contributes
to peritoneal metastasis by binding to the hyaluronan
coat on mesothelial cells [7–9]. In the cell’s interior,
CD44 is linked to the actin skeleton and thereby induces
the transformations to spindle morphology in EMT-like
changes [5].
MMPs also play a role in regulating EMT and thus in
promoting invasion and metastasis. MMPs are ubiqui-
tous zinc-dependent proteases that are important in nu-
merous physiological and pathophysiological processes,
including ovulation, reproduction, inflammation and
especially arthritis and cancer. In cancer, various MMPs
play an important role in progression and metastasis
[10]. In general, the greater the overexpression of MMPs
in primary and metastatic tumours, the worse the progno-
sis [11, 12]. In this study, we focused on MMP-14 [13, 14].
In EMT, MMP-14 and CD44 act jointly. The presence
of both molecules at the lamellopodia’s edge has been
demonstrated in cells undergoing EMT. [5] In vitro,
MMP-14 and CD44 form a complex at the lamellipodia
through the PEX domain in migrating cells [15].
When CD44 and MMP-14 are co-expressed in various
cancer cell lines, they stimulate cell migration after the
soluble part of CD44 is shed from the cell surface [16].
Various stimuli may trigger cleavage of the CD44 ectodo-
main, which is mediated by MMPs. This seems to indicate
that CD44 links MMP-14 and the actin cytoskeleton in
invasive cancer cells [5].
In vitro, cells overexpressing CD44 exhibit morpho-
logic changes from epithelial to mesenchymal features
with increased cell migration and invasion. CD44 overex-
pression in colon cancer cells has been shown to inhibit
E-cadherin expression, whereas it induces the expression
of EMT markers such as vimentin and MMP-14 [5].
The exact relationship between these molecules in the
EMT-like process in ovarian cancer has yet to be deter-
mined. Also not yet known is how EMT and the expres-
sion patterns of EMT markers correlate with clinical
outcome parameters such as debulking surgery and,
ultimately, survival. In a regional cohort study with 5-
year follow-up, the presence of MMP-14, CD44 and the
EMT markers E-cadherin and vimentin was studied
and correlated with the outcome of debulking surgery
and survival.
Methods
Clinical data
From the regional Registration System Oncological
Gynaecology (ROGY) all ovarian malignancies diag-
nosed between 1 January 2007 and 31 December 2008
were selected. This group consisted of 125 patients
diagnosed with primary ovarian cancer at Elisabeth
Tweesteden Hospital Tilburg, Amphia Hospital Breda,
St. Catharine Hospital Eindhoven and Jeroen Bosch
Hospital’s-Hertogenbosch, all in the Netherlands.
All patients were followed until 1 June 2013. Nine
patients died before the diagnosis could be histopatho-
logically confirmed. Seven patients were operated on in
other hospitals and tissue of eight patients was sent to
other hospitals for consultation or research; therefore, it
was not available for this study. In the case of four
patients, no tumor was found in the remaining paraffin-
embedded tissue, leaving 97 patients for analysis.
All patients underwent a laparotomy with staging or
debulking if such interventions were indicated by clinical
stage and frozen-section results. Debulking surgery was
found to be complete if no macroscopically visible or
palpable tumor tissue was present. In patients with
FIGO stage Ia or Ib ovarian cancer with differentiation
grade I, no adjuvant therapy was given. All other pa-
tients received six courses of adjuvant platinum-based
chemotherapy.
Data collection from the ROGY registry was prospective.
Additional clinical and follow-up data were collected from
the medical records. FIGO stage (I to IV) was categorized
according to 2014 criteria [17]. Serum levels of CA-125
were determined pre-operatively.
Since MMP-expression is influenced by chemotherapy,
only histopathological samples before chemotherapy
were used.
Histopathological data
All histopathological results were independently reviewed
by two gynecopathologists (PK, AAW). Consensus on
definitive results was reached in a joint consultation.
Histology and differentiation grade were categorized
according to World Health Organization (WHO) criteria,
the grade being assigned on the basis of the observer’s
impression of both architectural and cytological fea-
tures [18].
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Immunohistochemistry
From archives of the histopathology laboratories, paraffin-
embedded tumour blocks were selected. Immunohisto-
chemistry was performed as previously described [19]. In
brief, sections (3 μ) were deparaffinized in xylene and rehy-
drated with graded alcohol. Each slide included positive
controls for MMP’s consisting of placental tissue. Each run
included negative controls without a primary antibody. En-
dogenous peroxidase was blocked with 3 % H2O2 and 5 %
normal goat serum. After each incubation step, slides were
washed twice with PBS. As primary antibody for MMP-14,
a polyclonal antibody (Thermoscientific, Waltham, MA,
USA) in a dilution of 1:20 with incubation at roomtem-
perature (RT) for 60 min was used. As a primary antibody
for CD44, a polyclonal antibody (Proteintech, Manchester,
United Kingdom) in a dilution of 1:80 with incubation at
RT for 30 min was chosen. The primary antibody for
E-cadherin was a polyclonal antibody (Proteintech,
Manchester, United Kingdom) diluted 1:40 with incu-
bation at RT for 30 min and for vimentin, a polyclonal
antibody (Proteintech, Manchester, United Kingdom)
diluted 1:80 at RT for 30 min was used. After washing
with PBS, slides were incubated with a secondary anti-
body, poly-HRP-GAM/R/R IgG Powervision (Immuno-
logic, Duiven, the Netherlands) for 60 min at room
temperature. Staining was done with diaminobenzidine
(Immunologic, Duiven, the Netherlands) in substrate
buffer (20 μl/ml) for 5 min. Finally, the slides were
counterstained with hematoxylin.
Scoring of immunostaining
The scoring system used for MMP-14 incorporated staining
intensity (0 = absent, 1 = weak, 2 =moderate, 3 = strong)
and percentage of positive cells (0 = 0 %, 1 = 1–25 %, 2 =
26–50 %, 3 = 51–75 %, 4 = 76–100 % of cells). Stromal
staining was recorded separately [13]. Points for inten-
sity and percentage of positive tumor cells were added
into an Overall Score (OS) according to Kamat [13],
where 0 = no expression or < 5 % of cells positive, 1 =
weak expression (1–2 points), 2 =moderate expression
(3–4 points) and 3 = strong expression (5–6 points).
The overall score was dichotomized into 0 for no/weak
expression (1–2 points) and 1 for moderate-to-strong
expression (3–6 points).
For immunostaining with CD44 and E-cadherin, the
points for percentage of tumor cells stained and the
intensity of staining were added and the tumors were
dichotomized into two groups for each antibody: low
expression (OS = 0) and high expression (OS = 1). Low
expression included tumors with < 25 % staining, regard-
less of the intensity, and tumors with negative or weak
intensity. High expression included tumors with at least
25 % staining and average-to-strong intensity.
Regarding EMT, a tumor was scored as positive (OS = 1)
if vimentin was found to be expressed in at least 25 % of
the epithelial tumor cells, regardless of the intensity and
the expression pattern of other markers. For vimentin, the
percentage of positive cells was also determined for each
slide.
Two investigators scored all slides for immunohisto-
chemistry (EH, MCV). If they disagreed, consensus was
reached by consulting a gynaecopathologist (AAW).
Statistical analysis
Statistical analysis was performed using the Statistical
Package for Social Sciences 20.0 (SPSS Inc., Chicago, Il).
Descriptive statistics were used to describe patient charac-
teristics and immunohistochemistry scores of early-stage
and advanced-stage patients. For normally distributed
continuous variables, independent samples t-tests were
used, whereas for not normally distributed continuous
variables, Mann-Whitney tests were used. For categorical
variables, chi-square tests were used.
To determine the correlation coefficients between
MMP and EMT parameters, Spearman’s rho correlation
coefficients were calculated; a value of .1 being considered
small, .3 medium and .5 large.
A logistic regression was performed with complete or
incomplete debulking as the outcome parameter and
MMP-14 and EMT parameters as independent variables.
Results
Distribution of EMT-like changes within ovarian tumours
In Fig. 1, the immunohistochemical staining of all
markers used in this study is shown in a clear cell car-
cinoma. This illustrates the typical expression patterns
of the markers. MMP-14 is expressed both in the tumor
epithelium and in the stroma, whereas E-cadherin is
only expressed in the tumor epithelium. Vimentin is
mainly found in the stroma and CD44 is also found in
the tumor stroma, with increased expression close to the
tumor epithelium.
Expression patterns for the various EMT markers are
sometimes very heterogeneous. The first panel of Fig. 2
shows the distribution of positive staining of E-cadherin
in the tumor epithelium and negative staining in the
stroma (A). The second panel shows typical negative
staining for vimentin in the epithelium and positive
staining in the stroma (B) in an adjacent slide.
Figure 3 shows the heterogeneity of the various EMT
markers within an endometroid tumor. In the tumor,
epithelium close to the stroma shows positive staining
for CD44 (A), whereas staining with vimentin (B) or E-
cadherin (C) is negative at that site, this is indicated with
arrows [1]. At other sites within the same tumor, the
epithelium and stroma can exhibit positive or negative
expression of both vimentin (B) and E-cadherin (C).
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Fig. 1 Immunohistochemistry panel of a clear cell carcinoma in a 56-year old patient in FIGO stage IA with survival of 62 months without recurrence.
a haematoxylin-eosin, b MMP-14, c E-cadherin, d vimentin, e CD 44. Magnification 10 × 10
Fig. 2 Immunohistochemistry of a high graded serous carcinoma in a 62-year old patient who underwent debulking surgery followed by chemotherapy.
She recurred after 13 months and survived 41 months. The figure shows the distribution of positive staining for E-cadherin in the tumor epithelium and
negative staining in the stroma (a). The second panel shows negative staining for vimentin in the epithelium and positive staining in the stroma (b).
Magnification 10 × 10
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Generally, E-cadherin expression is hardly evident in the
stroma, whereas vimentin expression is abundant there.
However, some epithelial areas express not only E-
cadherin but also CD44 and vimentin.
Immunohistochemistry
The patient characteristics are summarized in Table 1.
The immunohistochemistry results are shown in Table 2.
A significant difference was found in the expression of
epithelial and stromal MMP-14 and CD44 between early-
stage and advanced-stage patients, MMP-14 being more
often expressed in the tumor epithelium in advanced-
stage patients than in early-stage patients and less often in
the tumor stroma. However, CD44 was less often found in
the tumor epithelium in advanced-stage tumors, though
one-third of the tumors expressed CD44 in the epithe-
lium. No statistically significant difference between early
and advanced-stage patients was found in the expression
of E-cadherin and vimentin.
Additional chi-square tests were done to find out if
these significant differences were attributable to histologic
subtype and this was not the case (results not shown).
The subgroup of patients with both MMP-14 and
CD44 expression differed from the group with no ex-
pression of both markers or expression of only one of
these markers. Only 53 % of tumors with co-expression
of MMP-14 and CD44 were of serous histology versus
72 % in the no/single-expression group; clear cell hist-
ology was 16 % versus 8 % in the co-expression group;
and unspecified histology was 10 % versus 4 % in the
adenocarcinoma group. Although complete debulking
was high in the advanced-stage patients (11/14 (80 %))
with co-expression of MMP14 and CD44, the median
overall survival was low (28 months versus 38 months in
the whole group of advanced-stage patients). In this
group, the expression of EMT markers E-cadherin and
vimentin showed no differences with the expression in
the whole group of patients (Table 2). Unfortunately, the
group is too small for statistical analysis.
Table 3 shows the Spearman correlations between histo-
logic subtype and MMP and EMT markers. The histo-
logical subtype correlated with CD44 expression (rho .286,
p < 0.01). Subgroup analysis indicated that the significant
correlation is determined by the correlation between
serous histology in advanced-stage patients for CD44
(rho .284, p 0.007). Moreover, CD44 expression correlated
with percentage vimentin expression (rho .217, p < 0.05).
Clinical outcome in terms of debulking surgery and survival
Logistic regression analysis with complete debulking as
dependent variable and MMP-14 and EMT parameters
as independent variables showed significance for epithelial
CD44 expression (OR (Odds Ratio) 3,571 (95 % Confi-
dence Interval 1,112–11,468) significance 0,032). MMP-14
expression was neither a confounder nor an interactor in
this relationship.
For survival, no significance for MMP-14 expression
nor for EMT parameters as E-cadherin or vimentin was
found.
Discussion
In this regional cohort with 5-year follow-up, the presence
of MMP-14, CD44 and the EMT markers E-cadherin and
vimentin and their interrelationships were investigated.
The patients with double expression of MMP-14 and
CD44 in their tumors had a poor prognosis despite
complete debulking. Serous subtype in advanced-stage
patients and CD44 expression were correlated with
Fig. 3 Immunohistochemistry of a well-differentiated endometrioid carcinoma in a 43-year old patient in FIGO stage IC who survived 73 months
without recurrence. The tumor shows heterogeneity for CD44 (a), vimentin (b) and E-cadherin (c), negative epithelial staining for CD44 and vimentin and
negative for E-cadherin and vice versa for stromal staining indicated with arrows. Negative staining for CD44 and vimentin and positive for E-cadherin
indicated with closed asterisks. The adjacent stroma is either negative or only weakly stained. Open asterisks indicate positive epithelial staining for CD44
and E-cadherin with negative stromal staining and negative epithelial vimentin staining with positive stromal staining. Magnification 10 × 10
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EMT markers and CD44 expression was found to be
significantly correlated with complete debulking.
It is a challenge to interpret these findings patho-
physiologically. A previous study found that CD44 ex-
pression is associated with peritoneal metastasis and
EMT [16], but it is not clear how peritoneal metastasis
and EMT are related to complete debulking. In our
study, epithelial CD44 expression was a predictor for
complete debulking, which is consistent with the better
prognosis for CD44-positive tumors [20].
To determine CD44 expression in this study, a pan-
CD44 antibody was used in order not to miss relevant
CD44 expression in the tumors. Pan-CD44 expression is
associated with a better prognosis in ovarian cancer,
though some other isoforms of CD44 are associated with
a poorer prognosis [7, 20, 21]. The first finding is con-
sistent with the correlation of CD44 with complete
debulking. These studies of somewhat older date
correlated CD44-isoforms with prognosis in ovarian can-
cer: in a small series a low frequency of CD44v5 and
CD44v6 were found [7]. In a larger series, CD44 was
present in about half of the tumours and indicated a good
prognosis [20]. In another series, CD44s, CD44v3 and
CD446 were upregulated in ovarian cancer, but declined
Table 1 Patient characteristics (numbers of patients unless
stated otherwise)
Early-stage
(FIGO IA-Ic)
(n = 23)
Advanced-stage
FIGO (IIB-IV)
(n = 74)
Total
(n = 97)
Age (median (min-max)) 59 (24–81) 64 (30–84) 62 (24–84)
Histological subtype
Low-grade serous 10 14 24
High-grade serous 0 42 42
Mucinous 4 4 8
Endometroid 1 3 4
Clear cell 6 2 8
Adenocarcinoma
unspecified
7 7
Mixed 2 2 4
Differentiation
Low-grade 12 18 30
High-grade 11 56 67
CA 125
(median (min-max))
61 (7–3222) 615 (9–37500) 332 (7–37500)
FIGO stage
IA-IC 23 23
IIB 14 14
III 44 44
IV 16 16
Debulking (only advanced stage disease)
Complete 62
Incomplete 12
Overall Survival (months
(minimum-maximum))
64 (28–75) 38 (0–76) 50 (0–76)
Number of deceased
patients
4 51 55
Table 2 Results of immunohistochemistry and description of
MMP-14/CD44 co-expression group
Early-stage
(n = 23)
Advanced-stage
(n = 74)
p value*
MMP-14 Overall Score
(number of patients)
0.07
0 8 11
1 10 42
MMP-14 stroma
(number of patients)
0.03
no 4 25
weak 14 23
strong 0 5
CD 44 Overall Score 0
0 6 47
1 15 21
E-cadherin Overall Score n.s.
0 0 1
1 21 67
Vimentin epithelial score 30 % 32 % n.s.
Group with co-expression
MMP-14-CD44a
5 14
Histological subtype
Serous 1 9
Mucinous 1 1
Endometroid 1 0
Clear cell 2 1
Adenocarcinoma unspecified 0 2
Mixed 0 1
Grade
Low-grade 1 3
High-grade 4 11
Debulking
Complete 11
Incomplete 3
E-cadherin Overall Score
0 0 1
1 5 13
Vimentin epithelial score 36 % 34 %
*p value based on T-test and chi-square between early-stage and advanced-
stage when appropriate
anumbers too small for statistical analysis, n.s. not significant
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with advancing FIGO stage [21]. In a series with lymph-
node metastasis, a high expression for CD44v5 and
CD44v6 was found [22]. Recently, CD44v6 was found to
correlate with prognosis while in another study, CD44v8-
10 indicated a better prognosis and a more epithelial
phenotype [23, 24]. A recent meta-analysis concluded that
only CD44s is related to chemoresistance in ovarian cancer
[25]. It may be that using an antibody for a specific isoform
of CD44 would have resulted in a different relationship
with EMT markers, because some isoforms of CD44 may
be more important than others in EMT, like CD44v8-10.
However, this is not fully studied in ovarian cancer. In
a study of colorectal cancer, the standard isoform CD44s
seemed to be correlated with EMT, but higher CD44 ex-
pression predicted poor survival in that study in contrast
to our results in ovarian cancer [26].
In other gynecological malignancies, the presence of
EMT-like changes has been found to indicate poor prog-
nosis [1]. Our study in ovarian cancer was not consistent
with that finding.
A tentative explanation for this apparent discrepancy
may be the pathology of ovarian tumors. Typically, a small
proportion of ovarian tumors invade the ovary internally
from their cystic lining, whereas the majority spread ex-
tensively on the peritoneum and to a lesser extent on the
ovarian surface. Therefore, the invasive front is difficult to
determine. Arguably, the superficial spreading on the peri-
toneal surface does not require the invasive properties of
cells with EMT-like changes. However, deep invasion into
other organs and metastasis into the liver for example do
occur in ovarian cancer patients, albeit infrequently. In
ovarian cancer, both changes to an EMT-like phenotype
as well as a reverse to MET (Mesenchymal-to Epithelial
Transition)-like changes are found [27].
The advantage of using an immunohistochemical
panel for EMT, as in this study, is that various aspects of
EMT in ovarian cancer are revealed.
One such aspect is the heterogeneous expression of
the markers. The pattern is either positive expression of
both E-cadherin and vimentin, negative expression of
both these markers, or positive expression of one and
negative expression of the other. Positive areas of E-
cadherin expression indicate an epithelial phenotype,
whereas positive expression of vimentin indicates a
mesenchymal phenotype. Figure 2 shows an area where
the expression patterns of E-cadherin and vimentin are
heterogeneous. Although this heterogeneous pattern
may be easy for the pathologist to interpret qualitatively,
it makes it difficult to score the immunohistochemical
results quantitatively, because in practice only the inten-
sity and percentage of the cells are scored and heteroge-
neous expression is difficult to quantitate.
We studied primary ovarian tumor tissue. EMT markers
in primary tumors may be expressed less than in metastatic
tumors, especially in advanced-stage disease, as has been
found for some CD44 isoforms. [22] It is the extent and
progression of metastatic disease that eventually deter-
mines prognosis in a particular patient.
Although we have found that, for these reasons, EMT-
like changes does not indicate prognosis in ovarian
cancer, some of our results are consistent with the hy-
pothesis that EMT is stimulated by CD44 and MMP-14
expression [5]. In the present study, the patients with
double expression of MMP-14 and CD44 in their tumor
had a poor prognosis. CD44 was found to be correlated
not only with serous histology in advanced-stage patients
but also with vimentin expression as a marker for EMT
(Table 3). These correlations have a magnitude of 0.2-0.3,
indicating a moderate effect. No correlation with EMT-
like changes was found for MMP-14.
However, the small subset of tumors with both
MMP-14 and CD44 expression seem to resemble type-I
tumors with a lower percentage of serous histology and a
higher percentage of clear cell and unspecified histology
[28]. As previously stated, the choice of CD44 isoform
to be measured may be important, as was described
in a study on a small series of clear cell carcinomas
where CD44-10v expression predicted recurrence and
death [29].
The lack of significance of EMT for prognosis in ovarian
cancer evident in the present study may also be due to the
cross-sectional study design, in which the tumors were
not followed in time. If a subset of the tumors with EMT-
like changes were to result in a poorer prognosis for those
patients, the statistical significance of this would be lost
due to dilution with patients in which EMT is irrelevant
to the clinical course. Solving this problem by collecting
large series of tumor samples and performing immunohis-
tochemistry on them requires preparation of such samples
in one laboratory according to a uniform protocol. Bias
may result in various ways, including missing samples and
different protocols for tissue handling and fixation in dif-
ferent hospitals and laboratories. A shortcoming of our
study was a relatively high number of missing samples for
the various markers.
A strength of our study was the prospective data collec-
tion via the ROGY registry, which is used to register pa-
tients in all of the participating hospitals and sign them up
Table 3 Correlations between histologic subtype and MMP-14
and EMT markers
Histologic subtype MMP-14 CD 44 E-cadherin
MMP-14 -0.13
CDv44 0.286b -0.07
E-cadherin -0.19 0.2 0.09
Percentage vimentin -0.05 -0.01 0.217a -0.18
aCorrelation is significant at the 0.05 level
bCorrelation is significant at the 0.01 level
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for the tumor board meeting. By selecting patients via this
registry and then collecting data from their hospital
records, a thorough follow-up was achieved.
Conclusion
From this cohort study on MMP-14 and CD44 expres-
sion in ovarian cancer, we conclude that the subgroup of
patients with positive expression of both MMP-14 and
CD44 had type-I tumors with poor prognosis despite
complete debulking. We have demonstrated the presence
and heterogeneity of EMT-like changes in ovarian cancer.
We have also found that serous histology in advanced-
stage patients and CD44 are correlated with vimentin ex-
pression and thus EMT-like changes. The most important
finding of this study is that CD44 expression is positively
related to complete debulking.
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